


RADAAAR

AMR Policy & Advocacy: Some Reflections


Satyajit Sarkar


International Vaccine Institute


15 JULY 2021



Battle Mantra of the Warrior Turtle







AMR Policymaking: Points of Intersection and Departure

The Known, the Unknown, and the possibly Unknowable


- Sources and pathways of transmission, and their relative contribution to AMR, are yet to be quantified -- needs reliable, timely, and quality data
- Burden of morbidity and mortality attributable to resistant infections is yet to be accurately estimated and will vary by setting and country contexts.

'Access versus Excess': Dilemmas Confronting LMICs

- Rising incomes and mobility
- High burden of infectious diseases
- Limited or delayed access to antibiotics
- Growth in consumer demand for livestock products
- Substandard and falsified drugs

... are together driving the emergence and spread of AMR.

Use of Data for Policymaking



Characterizing the AMR policy and planning ‘problem’

CHARACTERISTICS OF ‘WICKED PROBLEMS’

1. Difficult to clearly define the problem.
2. Have many interdependencies and are often multi-causal.
3. Attempts to address them often lead to unforeseen consequences
4. They are often not stable.
5. Usually do not have a clear solution.
6. They are socially complex.
7. Do not sit within the responsibility of any one organization.
8. Involves changing behavior.
9. Often characterized by chronic policy failure.


‘Super-wicked Problems’

1. Time is running out
2. There is no central authority, or only a weak central authority, to manage the problem
3. The same actors causing the problem are attempting to solve it
4. The future is discounted radically so that contemporary solutions become less valuable



“Usually, wicked problems require more than a whole-of-government approach: solutions require involving many social stakeholders, particularly citizens.”

Unpacking the AMR problem: The Cynefin Framework for Leaders & Decision-Making



Source : Snowden, D.J. and Boone, M.E. in *A Leader’s Framework for Decision Making*.
Harvard Business Review, Nov 2007.

Asks of AMR 'Strategic' or 'Technical' Policymakers

1. "Where are we today?"
2. "Where do we need to go?"
3. "How do we get there?"
4. "What works?"
5. "What's it going to cost?"



REQUIRED

- Reliable and up-to-date evidence
- In an easy-to-understand format
- That lends itself to weighing options

But It's Complicated

Emergence and spread of AMR is driven by human action/behaviors.

And there are close linkages to issues of:

- Livelihoods
- Public trust in the (health) authorities

RADAAR's Objectives

Identify barriers/enablers to data sharing and analysis




Establish mechanisms to facilitate policy dialogue



Create a demand for policy-relevant data

Unpacking 'Trust'



* Refers in this instance to public trust in the *motives* and *competence* of the (health) authorities.

Trust-Confidence-Cooperation Model of Risk Communication

Source: Adapted from the simplified version of Siegrist et al.'s (2003, 2005) model as depicted in Twyman et al. (2008, p 112)

PERCEIVED

**MOTIVES
COMPETENCE
FAIRNESS**

Building trust is a slow, complex, and long-term task.

Mechanically applying some operational guidelines or SOPs does not build trust.

Trust grows with the experience of *trustworthiness*.

Only one golden rule:

Talk Less, Listen More

AMR Advocacy & Communication: Incremental Steps or Quantum Leaps?

- Actions to address drug-resistant infections on the ground are simply not happening at the scale and urgency required.
- Groundswell of public and societal support needed to push and hold political leaders accountable.
- Current AMR communication and advocacy approaches need to be dramatically re-framed and scaled-up.

AMR:

**In search of a
'secondhand smoke'
moment?**

Framing of the AMR Problem and Response

Differential Framing and Discourse of the AMR Problem	
Policy Frame	Policy Focus and Intervention Characteristics
1. A healthcare issue	Focus on the healthcare sector; promotion of early diagnosis and treatment through rational/prudent use of antimicrobials and antimicrobial stewardship.
2. A development issue	The high burden of infectious diseases and lack of awareness in LMICs drives overuse and misuse of antimicrobials. Universal and equitable access to quality antimicrobials seen as a right to health. Achievement of SDGs imperiled.
3. An innovation issue	Lack of new compounds and diagnostics. Market failure and lack of incentives for R&D in the pharmaceutical sector. Incentivization of R&D through new mechanisms
4. A security issue	AMR viewed as a threat to individual and national (health) security as a result of globalization and imperiling the global North. Focused on systematic surveillance, capacity building, and containment of AMR 'at source' (i.e. largely the global South)
5. A One Health issue	Developed in the context and as a response to rising incidences of zoonoses and the large-scale overuse/misuse of antibiotics in food animal production, requiring multi-sectoral engagement. Globally endorsed overarching approach for containing AMR. Despite operationalization challenges, improved coordination and collaboration between human, animal, and environmental sectors is the policy response emphasis.
<p><i>Source: Adapted from Wernli, D., Jørgensen, P. S., Morel, C. M., Carroll, S., Harbarth, S., Levrat, N., & Pittet, D. (2017). Mapping global policy discourse on antimicrobial resistance. BMJ global health, 2(2), e000378.</i></p>	

Acknowledging and Foregrounding
the ‘Access versus Excess’ dilemma facing policymakers in LMICs

A Proposition

ESTABLISH:

1. **Attaining and Sustaining ‘National Antimicrobial Security’**
as the overarching **Strategic Goal of National Action Plans (NAPs)**

RECONFIGURE:

2. NAPs as a **Progressive Pathway** to achieving **‘National Antibiotic Security’**,
with a robust ‘Theory of Change’ and time-bound numerical targets.

A conceptual re-framing: *Attaining and Sustaining 'National Antimicrobial Security'*

Working Definition

Every country **retains the continued ability** to treat infectious **diseases of the highest burden** with **effective and safe antimicrobials** in an **affordable and equitable manner** by **preventing the emergence and spread** of AMR, and thereby **reducing the impact** of infectious disease on the **human, animal, environmental, and economic health** of the country.

Starting when?
By when?
Till when?

Which diseases or pathogens have become, or are becoming, resistant to the antimicrobials currently available and being used in the country?

Which infectious diseases have the highest burden and economic impact on the country?

Which antimicrobials have become, or are in imminent danger, of becoming ineffective in the country due to resistance or sub-standard quality?

Access to which important antimicrobials is being denied due to costs or availability?

What impacts can and need to be reduced, by how much, and by when?

What are the antimicrobial consumption and usage levels and patterns (including professional and social behaviors and practices) that are driving the emergence and spread of AMR?

Do the benefits outweigh the costs?
Which sector needs the highest investments?
Investments in which sector will bring the maximum and quickest benefits? Are the required investments affordable?


ASSURING



ACCESS
without
EXCESS

Linking the 'Technical' with the 'Social'

Contribution and ratio of social science versus science in The Web of Science



Source: Frid-Nielsen, S. S., Rubin, O., & Baekkeskov, E. (2019). The state of social science research on antimicrobial resistance. *Social Science & Medicine*, 242, 112596.

Surveillance Re-Imagined: 'Joined-up' Data Collection and Analysis

Annual Average Number of AMR Publications		Share of Social Science articles in the Social Sciences Citation Index
2000 - 2009	2010 - 2017	1956 - 2018
7,200	16,300	1,311

Source: Frid-Nielsen, S. S., Rubin, O., & Baekkeskov, E. (2019). The state of social science research on antimicrobial resistance. Social Science & Medicine, 242, 112596.

Emergence and spread of AMR is driven by human action/behaviors. AMR prevention and control will require strong linkages between epi-surveillance and socio-behavioral data:

- Intricate and complex link with livelihoods
- Prescribing habits, consumer/patient demands, farming practices
- The 'Political Economy' of AMR

Emerging Imperative (?)

Consider: A sentinel AMR Socio-Behavioural Surveillance System

Policy, Advocacy, Communication, and Social Mobilization (ACSM) Coalitions

DISEASE/ISSUE	COALITION	Lead Agencies
Polio Eradication	Global Polio Eradication Initiative	WHO, UNICEF, CDC, Rotary International + thousands of in-country Partners
HIV/AIDS	World AIDS Campaign	UNAIDS + thousands of CSOs/NGOs
Tuberculosis	Stop TB Partnership	Stop TB Partnership Sectt + thousands of CSOs/NGOs
Avian Influenza	One Health Partnership (emerged)	FAO-WHO-OIE + UNICEF + hundreds of CSOs/NGOs
Covid19/Ebola	RCCE Collective Service	WHO, UNICEF, IFRC, GOARN + dozens of in-country Partners
AMR	???	(ReACT? Tripartite? Others?)

So, when it comes to 'data', remember...

“Not everything that can be counted counts,
and not everything that counts can be counted.”

(Attributed to multiple sources)

It just needs to be policy-relevant.

Thank you

Satyajit Sarkar
RADAAR, International Vaccine Institute
satyajit.sarkar@ivi.int

